Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

50 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Plasma levels, safety, and 60-week efficacy of a once-daily double-boosted protease inhibitor regimen of atazanavir, saquinavir, and ritonavir.
Manosuthi W, Sungkanuparph S, Ruxrungtham K, Prasithsirikul W, Athichathanabadi C, Tantisiriwat W, Bowonwatanuwong C, Chumpathat N, Chaovavanich A. Manosuthi W, et al. Among authors: bowonwatanuwong c. J Acquir Immune Defic Syndr. 2008 Jan 1;47(1):127-9. doi: 10.1097/QAI.0b013e318157b0da. J Acquir Immune Defic Syndr. 2008. PMID: 18156994 No abstract available.
Efavirenz-based regimen as treatment of advanced AIDS with cryptococcal meningitis.
Sungkanuparph S, Vibhagool A, Mootsikapun P, Chetchotisakd P, Tansuphaswaswadikul S, Bowonwatanuwong C, Chantratita W. Sungkanuparph S, et al. Among authors: bowonwatanuwong c. J Acquir Immune Defic Syndr. 2003 May 1;33(1):118-9. doi: 10.1097/00126334-200305010-00019. J Acquir Immune Defic Syndr. 2003. PMID: 12792366 Clinical Trial. No abstract available.
Efficacy and tolerability of a double boosted protease inhibitor (lopinavir + saquinavir/ritonavir) regimen in HIV-infected patients who failed treatment with nonnucleoside reverse transcriptase inhibitors.
Chetchotisakd P, Anunnatsiri S, Mootsikapun P, Kiertiburanakul S, Anekthananon T, Bowonwatanuwong C, Kowadisaiburana B, Supparatpinyo K, Ruxrungtham K; Study Team. Chetchotisakd P, et al. Among authors: bowonwatanuwong c. HIV Med. 2007 Nov;8(8):529-35. doi: 10.1111/j.1468-1293.2007.00506.x. HIV Med. 2007. PMID: 17944686 Free article. Clinical Trial.
Guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents: the recommendations of the Thai AIDS Society (TAS) 2008.
Sungkanuparph S, Anekthananon T, Hiransuthikul N, Bowonwatanuwong C, Supparatpinyo K, Mootsikapun P, Chetchotisakd P, Kiertiburanakul S, Tansuphaswadikul S, Buppanharun W, Manosuthi W, Techasathit W, Ratanasuwan W, Tantisiriwat W, Suwanagool S, Leechawengwongs M, Ruxrungtham K; Thai AIDS Society. Sungkanuparph S, et al. Among authors: bowonwatanuwong c. J Med Assoc Thai. 2008 Dec;91(12):1925-35. J Med Assoc Thai. 2008. PMID: 19133532
The interrelated transmission of HIV-1 and cytomegalovirus during gestation and delivery in the offspring of HIV-infected mothers.
Khamduang W, Jourdain G, Sirirungsi W, Layangool P, Kanjanavanit S, Krittigamas P, Pagdi K, Somsamai R, Sirinontakan S, Hinjiranandana T, Ardonk W, Hongsiriwon S, Nanta S, Borkird T, Lallemant M, McIntosh K, Ngo-Giang-Huong N; Program for HIV Prevention and Treatment (PHPT) Study Group. Khamduang W, et al. J Acquir Immune Defic Syndr. 2011 Oct 1;58(2):188-92. doi: 10.1097/QAI.0b013e31822d0433. J Acquir Immune Defic Syndr. 2011. PMID: 21792064 Free PMC article.
A randomized comparison of second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir in patients failing NNRTI regimens: the HIV STAR study.
Bunupuradah T, Chetchotisakd P, Ananworanich J, Munsakul W, Jirajariyavej S, Kantipong P, Prasithsirikul W, Sungkanuparph S, Bowonwatanuwong C, Klinbuayaem V, Kerr SJ, Sophonphan J, Bhakeecheep S, Hirschel B, Ruxrungtham K; HIV STAR Study Group. Bunupuradah T, et al. Among authors: bowonwatanuwong c. Antivir Ther. 2012;17(7):1351-61. doi: 10.3851/IMP2443. Epub 2012 Jul 2. Antivir Ther. 2012. PMID: 23075703 Clinical Trial.
Low-dose versus standard-dose ritonavir-boosted atazanavir in virologically suppressed Thai adults with HIV (LASA): a randomised, open-label, non-inferiority trial.
Bunupuradah T, Kiertiburanakul S, Avihingsanon A, Chetchotisakd P, Techapornroong M, Leerattanapetch N, Kantipong P, Bowonwatanuwong C, Banchongkit S, Klinbuayaem V, Mekviwattanawong S, Nimitvilai S, Jirajariyavej S, Prasithsirikul W, Munsakul W, Bhakeecheep S, Chaivooth S, Phanuphak P, Cooper DA, Apornpong T, Kerr SJ, Emery S, Ruxrungtham K; LASA Study Group. Bunupuradah T, et al. Among authors: bowonwatanuwong c. Lancet HIV. 2016 Aug;3(8):e343-e350. doi: 10.1016/S2352-3018(16)30010-8. Epub 2016 May 24. Lancet HIV. 2016. PMID: 27470026 Clinical Trial.
Discontinuation of secondary prophylaxis for cryptococcal meningitis in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy: a prospective, multicenter, randomized study.
Vibhagool A, Sungkanuparph S, Mootsikapun P, Chetchotisakd P, Tansuphaswaswadikul S, Bowonwatanuwong C, Ingsathit A. Vibhagool A, et al. Among authors: bowonwatanuwong c. Clin Infect Dis. 2003 May 15;36(10):1329-31. doi: 10.1086/374849. Epub 2003 May 2. Clin Infect Dis. 2003. PMID: 12746781 Clinical Trial.
High rate multiple drug resistances in HIV-infected patients failing nonnucleoside reverse transcriptase inhibitor regimens in Thailand, where subtype A/E is predominant.
Chetchotisakd P, Anunnatsiri S, Kiertiburanakul S, Sutthent R, Anekthananon T, Bowonwatanuwong C, Kowadisaiburana B, Supparatpinyo K, Horsakulthai M, Chasombat S, Ruxrungtham K; Study Team. Chetchotisakd P, et al. Among authors: bowonwatanuwong c. J Int Assoc Physicians AIDS Care (Chic). 2006 Dec;5(4):152-6. doi: 10.1177/1545109706294288. J Int Assoc Physicians AIDS Care (Chic). 2006. PMID: 17101807
50 results